Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Neoplasms 4Leukemia, B-Cell 3Recurrence 2Leukemia 2Bronchiolitis Obliterans Syndrome 2Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Autoimmune Diseases of the Nervous System 1Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1

Interventions

tofacitinib 7Imatinib Mesylate 5ibrutinib 3ofatumumab 2nilotinib 2ruxolitinib 1canakinumab 1bosutinib 1Sirolimus 1Rituximab 1Proto-Oncogene Proteins c-raf 1Photopheresis 1Pentostatin 1Mycophenolic Acid 1Methotrexate 1Infliximab 1Everolimus 1Etanercept 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Bronchiolitis Obliterans Syndrome × ofatumumab × Clear all
NCT01578707 2019-12-18

RESONATEâ„¢

Pharmacyclics LLC.

Phase 3 Completed
391 enrolled 14 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01313689 2018-11-08

Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

Novartis

Phase 3 Completed
122 enrolled 24 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡